The advent of Continuous Ketone Monitoring technology emerges as a promising solution, offering the potential to closely monitor ketone levels and provide real-time alerts to prevent DKA, thus addressing a critical barrier to the broader application of SGLT2-is in managing heart failure among patients with T1D. The gene discussed is SLC5A2; the disease is heart failure.